It was recently reported that the combination of pembrolizumab (anti-PD1 immunotherapy) plus docetaxel was well tolerated and substantially improved progression-free survival and overall response rate in patients with advanced NSCLC after platinum-based chemotherapy, including patients with EGFR variations [95]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.